Takeda Pharmaceutical (TAK) Short term Debt (2018 - 2026)

Takeda Pharmaceutical's Short term Debt history runs 9 years deep, the most recent figure standing at $3.6 billion for Q1 2026.

• In Q1 2026, Short term Debt rose 0.88% year-over-year to $3.6 billion; the TTM figure through Mar 2026 stood at $3.6 billion (up 0.88% YoY), while the FY2026 annual figure was $3.8 billion, up 4.93% from the prior year.
• Short term Debt was $3.6 billion for Q1 2026 at Takeda Pharmaceutical, down from $3.7 billion in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $4.0 billion in Q3 2023 to a low of $967.8 million in Q1 2024.
• Historically, Short term Debt has averaged $3.4 billion across 5 years, with a median of $3.7 billion in 2025.
• The sharpest annual moves came in 2022 and 2024: Short term Debt soared 706.13% in 2022, then slumped 62.3% in 2024.
• A 5-year view of Short term Debt shows it stood at $3.6 billion in 2022, then climbed by 2.9% to $3.7 billion in 2023, then grew by 6.03% to $3.9 billion in 2024, then fell by 4.98% to $3.7 billion in 2025, then declined by 1.42% to $3.6 billion in 2026.
• The last three Short term Debt figures came in at $3.6 billion (Q1 2026), $3.7 billion (Q4 2025), and $3.7 billion (Q3 2025), per Business Quant data.